首页> 外文OA文献 >Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

【2h】

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

机译：通过CD3双特异性和ADC方式定位CLDN18.2治疗胃癌和胰腺癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Guoyun Zhu; Davide Foletti; Xiaohui Liu; Sheng Ding; Jody Melton Witt; Adela Hasa-Moreno; Mathias Rickert; Charles Holz; Laura Aschenbrenner; Amy H. Yang; Eugenia Kraynov; Winston Evering; Leslie Obert; Chenyu Lee; Tao Sai; Tina Mistry; Kevin C. Lindquist; Thomas Van Blarcom; Pavel Strop; Javier Chaparro-Riggers; Shu-Hui Liu;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer [J] . Guoyun Zhu, Davide Foletti, Xiaohui Liu, Scientific reports. . 2019,第1期

机译：作者校正：针对CLDN18.2通过CD3双特异性和ADC方式进行胃癌和胰腺癌治疗
2. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma [J] . Siler H. Panowski, Tracy C. Kuo, Yi Zhang, Molecular cancer therapeutics . 2019,第11期

机译：CD3双特异性和ADC算法靶向BCMA治疗多发性骨髓瘤的临床前疗效与安全比较
3. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma [J] . Alexei V. Salnikov, Ariane Groth, Anja Apel, Journal of cellular and molecular medicine. . 2009,第9b期

机译：双特异性抗体EpCAMxCD3靶向癌症干细胞标志物EpCAM抑制胰腺癌
4. Expression and Significance of CD34 in Gastric Cancer [C] . W. Kielan, A. Haton, G. Mazur, International Gastric Cancer Congress . 2005

机译：CD34在胃癌中的表达及意义
5. CD16xCD33 bispecific killer cell engager (BiKE) activates natural killer (NK) cells from myelodysplastic syndrome (MDS) patients against primary MDS and myeloidderived suppressor cell (MDSC) CD33-positive targets. [D] . Gleason, Michelle K. 2014

机译：CD16xCD33双特异性杀伤细胞接合剂（BiKE）激活来自骨髓增生异常综合征（MDS）患者的自然杀伤（NK）细胞，以抵抗原发性MDS和髓样抑制细胞（MDSC）CD33阳性靶标。
6. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer [O] . Guoyun Zhu, Davide Foletti, Xiaohui Liu, -1

机译：通过CD3双特异性和ADC方式靶向CLDN18.2治疗胃癌和胰腺癌
7. Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer [O] . Guoyun Zhu, Davide Foletti, Xiaohui Liu, 2019

机译：作者校正：针对CLDN18.2通过CD3双特异性和ADC方式进行胃癌和胰腺癌治疗

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅